close encounters:
of healthy kind, of servant leader kind, of food security, of education kind, of credit kind, of solar kind, of other machine intel kind
37th year of economist debate- who will get last mile in time forpost-covid's sdg generation?- biden?, africa?, bangladesh?, far east islands, rest asia continent, euro, latinam, womens lives, colored second most exciting moment in life- meeting sir fazle abed 1 2- he had designed a rural health service for one of the ten most populous nations from scratch? which do you think sir fazle need more help from health genii or financial genii? -more here

2020 telehealth hinge moment
our biggest challenge in 2020s is not the virus it is failing to unite around designing a world so next girl or boy born has a joyful chance at a productive life- that depends on 3 skills thriving in ever community - the health servant (, the livelihood educator ( and the financial servant (
however we have known since the end of world war 2 that we need new maps than those that 8 largest empires had ruled planet with - and that 4 new technologies and types of mediation will multiply this sustainably up or crashing down until mother natures selects us as next dod- more at
who published 13 global health challenges 1/13/2020 - help update them -related search malaria : fda -messy

virus unknowns help unwomens list some twitter dialogues 1 2 3
ByeBye human race unless you can help us find medical word's top 10 World Record Jobs Creators 9 8 7 ...Ironically knowledge of the curriculum of entrepreneurial revolution - as the net generation's opportunity to collaborate in human sustainability peaked in 1984 - unless you can help World Record Jobs Creators retrieve it now - thanks chris macrae wash dc text 240 316 8157 Anyone seriously transparent about affordable global health and sustainability needs to develop segments of health services and then decide whether an integrated service is still to have place boundaries. THE BLOCKCHAIN WARS. New media is always a battle between the forces for evil who linkin fast and those who needed to open space for a deeper social order (which takes time). Understanding blockchain mapping will also be absolutely essential: it may be how sustainability's last call is won by little sisters or lost to big brothers. these are the most exciting times to be alive.. 4 markets human sustainability depends on health & . linkedin UNwomens - question collab blog editors: washington DC

china; Qatar bangladesh and asean ghana france india


good news china's robot teachers assistants will soon be better at diagnosis than 99% of docs. china

online library of norman record jobs creators: sir fazle abed .. jim kim.JKU. larry brilliant.. gerge soros..paul farmer .leana wen .BillionGirlsBoys network

Thursday, October 5, 2017

Guadalajara, Mexico | 11 – 14 October 2017

endTB Symposium: Accelerating TB elimination through access to bedaquiline and delamanid Hall 10 - Jalisco Hall October 12 14:00 – 15:30
The symposium will provide an update on the UNITAID-funded endTB initiative and findings, including culture conversion and reversion and adverse events for the 600 people who have received bedaquiline or delamanid.
Community space (Encuentro) session: Five urgent improvements to DR-TB treatment Foro - Encuentro Expo October 13 17:00 – 18:00
Evidence for treatment with newer DR-TB drugs, shorter treatment regimens, ambulatory care instead of hospitisation, and fast-track registration of new drugs.
MSF Symposium: Reducing catastrophic costs for people with TB through patient-centred care Hall 10 - Jalisco Hall October 14 10:30 – 12:00
Session will analyse the barriers to reducing costs and burden for people with drug-resistant TB including: decentralised and ambulatory treater, shorter treatment and newer drugs to reduce toxicity, and interventions to reduce out-of-pocket costs of treatment.

Many national TB programmes are out of step with international recommendations for testing, treatment and prevention: results of a 30 country survey Hall 2 – Events Ballroom October 12 16:00 – 17:30 SOA-365-12
Setting up an active pharmacovigilance system for the endTB project Hall 13 - Jalisco Hall October 13 10:30 – 12:00 OA-160-13
Early safety and efficacy of bedaquiline and delamanid combination for drug-resistant TB in Armenia, India and South Africa Plenary Hall October 13 10:30-12:00 OA-2905-13
Adverse events over 6 months with delamanid in a programmatic setting in Khayelitsha, South Africa Hall 13 – Jalisco Hall October 13 10:30 – 12:00 OA-162-13
Safety of multidrug resistant tuberculosis treatment amongst patients receiving bedaquiline in a compassionate use program in Armenia and Georgia Hall 13 – Jalisco Hall October 13 10:30 – 12:00 OA-163-13
Risk factors for developing hypothyroidism among MDR-TB patients receiving Eto and/or PAS in Maputo, Mozambique Hall 13 – Jalisco Hall October 13 10:30 – 12:00 OA-164-13
Psychiatric comorbidity among drug-resistant tuberculosis patients Hall 13 – Jalisco Hall October 13 10:30 – 12:00 OA-167-13
Culture conversion and reversion of multidrug resistant tuberculosis patients receiving bedaquiline in a compassionate use program in Armenia and Georgia Hall 13 – Jalisco Hall October 13 16:00 – 17:30 OA-188-13
Bedaquiline- and linezolid-based regimens for fluoroquinolone-resistant MDR-TB: how much better is it? Hall 13 – Jalisco Hall October 13 16:00 – 17:30 OA-190-13
Outcomes of multidrug resistant tuberculosis patients receiving Bedaquiline in a compassionate use program in Armenia and Georgia Hall 13 – Jalisco Hall October 13 16:00 – 17:30 OA-192-13
Delamanid for rifampicin-resistant tuberculosis: an observational cohort study from Khayelitsha, South Africa Hall 13 – Jalisco Hall October 13 16:00 – 17:30 OA-193-13
Value of determine-TB LAM test as screening test and as diagnostic tool for tuberculosis diagnosis in HIV positive adults Hall 8 – Events Ballroom October 13 10:30 – 12:00 SOA-402-13
Cost-effectiveness of including determine TB-LAM test to diagnose tuberculosis in HIV-positive symptomatic patients Hall 4 – Events Ballroom October 14 10:30 – 12:00 SOA-443-14
Incidence of latent tuberculosis infection and tuberculosis disease after 24 months follow-up in paediatric contacts of drug-resistant tuberculosis patients in Armenia Hall 13 - Jalisco Hall October 12 14:00 – 15:30 SOA-360-12
High rates of active hepatitis C amongst multidrug resistant tuberculosis patients in Armenia Hall 14 - Jalisco Hall October 12 10:30 – 12:00 OA-125-12
All poster prentations take place in the Poster Area from 12:45 – 13:45 on the designated date

Threats to affordable quality second-line TB drugs in Eastern Europe/Central Asia as the Global Fund shifts to national procurement October 14 PD-893-14
Introduction of a short standardized course of treatment for multidrug-resistant Tuberculosis in Mozambique: cohort description and early culture conversion in HIV-positive and HIV-negative patients October 12 PD-537-12
Outcomes and risk factors in a program treating MDR-TB in Swaziland for 2011-2013 cohorts October 12 PD-547-12
Drug induced hypothyroidism during treatment for multidrug resistant tuberculosis in Swaziland October 13 PD-685-13
Lessons learned from the design, development, and deployment of endTB electronic medical record for MDR-TB across 16 countries October 13 PD-700-13
Interim report on the use of a short, simplified regimen for the treatment of children with multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan October 13 PD-809-13
Accelerating access to delamanid for rifampicin-resistant tuberculosis in Khayelitsha, South Africa October 14 PD-891-14
The impact of pyrazinamide resistance upon the treatment outcome of patients with multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan October 14 PD-894-14
Evaluation of the OMNIgene® SPUTUM reagent for long term transportation of samples for Xpert testing in a high TB-HIV setting October 13 PD-837-13
Does the determine-TB LAM test have a potential value in tuberculosis diagnosis among severely acute malnourished (SAM) children? October 14 PD-924-14
Discordances between TST and IGRA to detect latent tuberculosis infection in paediatric contacts of drug-resistant tuberculosis patients October 14 PD-944-14
For MSF TB reports, go to:
· Out of Step 2017:
· DR-TB Drugs Under the Microscope, 5th Edition (COMING SOON)

1 comment: